The Panel’s investigation found that BP drilling engineers did not evaluate or communicate the ongoing risk associated with the following: The production casing shoe was set in a laminated sand‐shale interface in lieu of a consolidated shale; Deciding not to set an additional production casing barrier, such as, setting a retainer and/or cement plug above the float collar; Substantial (greater than 3,000 bbls) mud losses had occurred in the open‐hole production interval, which indicated potential cementing problems; The planned positive testing of the casing would have only tested the top wiper plug and not the cement casing track below the plug; The float collar was not a mechanical barrier to well flow; No cement was left above the float collar so that there would be enough room to run a cement evaluation log; the log was never run; The M56A and M56E sands were potentially unstable because of a difference in pore pressures; and There was a potential for ballooning in the open‐hole production interval from 17,168 feet to 18,360 feet. Instead of using the recommended risk assessment tool (the BP RAT system), the Macondo engineering team used a risk register, which was a spreadsheet that the team created to anticipate risks and to identify individuals assigned to mitigate risks. John Guide testified that a register or “ledger” was used throughout the process of drilling the well. 432 The Macondo team did not perform any risk analyses (or mitigation analyses) using the risk register after June 20, 2009. 433 Thus, the risk register was only utilized during the Macondo well design phase and not during BP’s execution of day‐to‐day operations at the well. In the risk register, BP personnel identified 23 risks while planning the well. BP personnel placed these risks into only three different categories – cost, production and schedule – and chose not to categorize any of them as “health and safety” risks. For example, BP personnel identified a well control problem as a “cost” and not a “health and safety” risk. The risk categories available in the
Guide testimony, July 22, 2010, at 64. BP‐HZN‐MBI 00269180; see Appendix J.
432 433
177